<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Arq. Bras. Cardiol</journal-id><journal-id journal-id-type="publisher-id">abc</journal-id><journal-title-group><journal-title>Arquivos Brasileiros de Cardiologia</journal-title></journal-title-group><issn pub-type="ppub">0066-782X</issn><issn pub-type="epub">1678-4170</issn><publisher><publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27142792</article-id><article-id pub-id-type="pmc">4845700</article-id><article-id pub-id-type="doi">10.5935/abc.20160048</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Endothelial Effect of Statin Therapy at a High Dose Versus Low Dose
Associated with Ezetimibe</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Garcia</surname><given-names>Maristela Magnavita Oliveira</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Varela</surname><given-names>Carolina Garcez</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Silva</surname><given-names>Patricia Fontes</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Lima</surname><given-names>Paulo Roberto Passos</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>G&#x000f3;es</surname><given-names>Paulo Meira</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Rodrigues</surname><given-names>Marilia Galeffi</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Silva</surname><given-names>Maria de Lourdes Lima Souza e</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Ladeia</surname><given-names>Ana Marice Teixeira</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Guimar&#x000e3;es</surname><given-names>Arm&#x000ea;nio Costa</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Correia</surname><given-names>Luis Claudio Lemos</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="c1"/></contrib><aff id="aff1">Escola Bahiana de Medicina e Sa&#x000fa;de P&#x000fa;blica (EBMSP)-
FBDC, Salvador, BA - Brazil</aff></contrib-group><author-notes><corresp id="c1"><bold>Mailing Address: Luis C. L. Correia</bold>, Av. Princesa
Leopoldina, 19/402. Postal Code 40.150-080, Salvador, BA - Brazil. E-mail:
<email>lccorreia@cardiol.br</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>4</month><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>4</month><year>2016</year></pub-date><volume>106</volume><issue>4</issue><fpage>279</fpage><lpage>288</lpage><history><date date-type="received"><day>31</day><month>12</month><year>2014</year></date><date date-type="rev-recd"><day>10</day><month>11</month><year>2015</year></date><date date-type="accepted"><day>24</day><month>11</month><year>2015</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>The effect of statins on the endothelial function in humans remains under
discussion. Particularly, it is still unclear if the improvement in
endothelial function is due to a reduction in LDL-cholesterol or to an
arterial pleiotropic effect.</p></sec><sec><title>Objective</title><p>To test the hypothesis that modulation of the endothelial function promoted
by statins is primarily mediated by the degree of reduction in
LDL-cholesterol, independent of the dose of statin administered.</p></sec><sec><title>Methods</title><p>Randomized clinical trial with two groups of lipid-lowering treatment (16
patients/each) and one placebo group (14 patients). The two active groups
were designed to promote a similar degree of reduction in LDL-cholesterol:
the first used statin at a high dose (80 mg, simvastatin 80 group) and the
second used statin at a low dose (10 mg) associated with ezetimibe (10 mg,
simvastatin 10/ezetimibe group) to optimize the hypolipidemic effect. The
endothelial function was assessed by flow-mediated vasodilation (FMV) before
and 8 weeks after treatment.</p></sec><sec><title>Results</title><p>The decrease in LDL-cholesterol was similar between the groups simvastatin 80
and simvastatin 10/ezetimibe (27% &#x000b1; 31% and 30% &#x000b1; 29%,
respectively, p = 0.75). The simvastatin 80 group presented an increase in
FMV from 8.4% &#x000b1; 4.3% at baseline to 11% &#x000b1; 4.2% after 8 weeks
(p = 0.02). Similarly, the group simvastatin 10/ezetimibe showed improvement
in FMV from 7.3% &#x000b1; 3.9% to 12% &#x000b1; 4.4% (p = 0.001). The placebo
group showed no variation in LDL-cholesterol level or endothelial
function.</p></sec><sec><title>Conclusion</title><p>The improvement in endothelial function with statin seems to depend more on a
reduction in LDL-cholesterol levels, independent of the dose of statin
administered, than on pleiotropic mechanisms.</p></sec></abstract><kwd-group><kwd>Endothelium / physiology</kwd><kwd>Cholesterol</kwd><kwd>Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use</kwd><kwd>Ezetimibe</kwd><kwd>Anticholesterolemic Agents</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The cardiovascular benefits of cholesterol-reducing statin therapy have been
demonstrated in primary<sup><xref rid="r1" ref-type="bibr">1</xref></sup> and
secondary<sup><xref rid="r2" ref-type="bibr">2</xref></sup> prevention
scenarios, and the improvement in endothelial function is one of the involved
mechanisms. This mechanism is credited to the lipid-lowering effect of the statins,
supported by the association between the magnitude of the reduction in cholesterol
and a reduction in cardiovascular risk.<sup><xref rid="r3" ref-type="bibr">3</xref></sup> On the other hand, some authors suggest that the improvement in
endothelial function is also mediated by pleiotropic actions<sup><xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r5" ref-type="bibr">5</xref></sup> independent of cholesterol: anti-inflammatory, antioxidant, and
antithrombotic effects.<sup><xref rid="r6" ref-type="bibr">6</xref>-<xref rid="r8" ref-type="bibr">8</xref></sup>
</p><p>These observations are based on <italic>in vitro</italic> studies. However, clinical
confirmation has been limited by the challenge of isolating the theoretical
pleiotropic effect of the statins from their lipid-lowering effect. The emergence of
ezetimibe as a drug to treat hypercholesterolemia offers a scientific model suitable
to test the pleiotropic hypothesis, since it allows a similar degree of reduction in
LDL-cholesterol with a lower statin dose.<sup><xref rid="r9" ref-type="bibr">9</xref></sup> For a similar reduction in cholesterol, higher doses of
statin promoting greater endothelial benefit than smaller doses would represent
clinical evidence in favor of a pleiotropic action. This model is based on the fact
that ezetimibe does not interfere in the mevalonate pathway, and its effect is only
mediated by the intestinal absorption of cholesterol.<sup><xref rid="r10" ref-type="bibr">10</xref></sup>
</p><p>We conducted this randomized clinical trial to test the hypothesis that the factor
influencing the endothelial function is the decrease in LDL-cholesterol, regardless
of the dose of statin administered. In this study, the outcome of the statin effect
on the endothelial function was evaluated by comparing the degree of arterial
flow-mediated vasodilation (FMV) in individuals randomized to a high dose of
simvastatin <italic>versus</italic> a low dose of simvastatin associated with
ezetimibe.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study Design</title><p>Clinical randomized, double-blind, placebo-controlled trial, registered at
ClinicalTrials.gov with the identifier NCT01241097, carried out at the Obesity
Outpatient Clinic of <italic>Escola Bahiana de Medicina e Sa&#x000fa;de
P&#x000fa;blica</italic> in Salvador, Bahia, Brazil. The study was approved
by the Ethics Committee of the institution under the protocol number 157/2009,
and all participants signed a free and informed consent form.</p></sec><sec><title>Cohort Selection</title><p>Women attending the clinic were consecutively selected based on the following
inclusion criteria: age above 18 years, body mass index (BMI) &#x0003e; 25 kg/m&#x000b2;, and
LDL-cholesterol &#x0003e; 100 mg/dL. We defined the following as exclusion criteria:
use of statin, ezetimibe, fibrate, or hormone replacement therapy within the
previous 3 months; triglyceride level &#x0003e; 400 mg/dL; serum creatinine above 2.0
mg/dL; hepatic enzymes levels at least 1.5 times above the normal reference
limit; serum creatine kinase (CPK) level higher than three times the upper
normal limit; pregnancy or lactation; and occurrence of cardiac insufficiency,
collagenosis, acute inflammatory conditions, or psychiatric disease. We also
excluded patients who had started beta-blockers, angiotensin-conversion
inhibitors, or calcium-channel blockers within the prior 4 weeks and those with
a brachial artery diameter below 2.5 mm, since the measurement of the degree of
dilation is compromised in these cases.</p></sec><sec><title>Study Protocol</title><p>After enrollment, the participants were randomized in blocks of three to the
following treatment modalities: 1) simvastatin 80 mg, 2) simvastatin 10 mg plus
ezetimibe 10 mg, and 3) placebo (<xref ref-type="fig" rid="f1">Figure 1</xref>).
We used the following criteria for early therapy interruption: medication
intolerance, increase in liver enzymes levels three times above the upper normal
level, or isolated measurement of CPK exceeding 10 times the upper normal
level.</p><p><fig id="f1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Flowchart of the study protocol.</p></caption><graphic xlink:href="abc-106-04-0279-g01"/></fig>
</p><p>We performed three sequential evaluations to analyze the endothelial function and
collect laboratory data: the first was before the beginning of the treatment,
the second was after 4 weeks of treatment, and the third was after 8 weeks of
treatment and represented the final assessment. During these evaluations, we
recorded possible adverse events, which we rated as major (rhabdomyolysis, liver
failure, renal failure, pancreatitis, obstructive jaundice, and death),
intermediate (myalgia, diarrhea, and vomiting, among others), and minor
(constipation, nausea and flatulence, among others).</p></sec><sec><title>Biochemical Analysis</title><p>We collected blood after 12 hours of fasting following the techniques and methods
standardized by the <italic>Sociedade Brasileira de Patologia
Cl&#x000ed;nica</italic> (Brazilian Society of Clinical Pathology). We
determined C-reactive protein levels with a commercially available
high-sensitivity nephelometric method<sup><xref rid="r11" ref-type="bibr">11</xref></sup> (Dade Behring Inc., Newark, DE, USA). Plasma
concentrations of total cholesterol, HDL-cholesterol, and triglycerides were
determined with a biochemical enzyme method (Dade Behring Inc., Newark, DE,
USA).</p></sec><sec><title>Brachial Artery Flow-Mediated Vasodilation</title><p>All participants were previously instructed to fast, not perform physical
activity, drink coffee, use medications, or smoke on the day of the test. The
adherence to these instructions was checked before the procedure.</p><p>We used ultrasonography with high-resolution color Doppler (Vivid 3, GE). The
evaluation was performed according to a previously published
guideline,<sup><xref rid="r12" ref-type="bibr">12</xref></sup> and the
volunteers were evaluated after fasting for 4 hours and resting while lying down
for 10 minutes in a room with controlled temperature (22&#x000b0; to 24&#x000b0; C). The tests
were performed by a single examiner who was blinded to the participants' data.
Simultaneous electrocardiographic monitoring, coupled to the ultrasound system,
allowed synchronization with the cardiac cycle. The brachial artery was
identified in the longitudinal axis at 3 centimeters above the antecubital fossa
and demarcated in the skin with a brush to prevent its position to change or
tilt. A longitudinal image of 6 to 8 centimeters was obtained as a baseline
reference. We then assessed the flow and estimated the average speed of a sample
volume in the center of the artery, with a 60&#x000b0; vessel angulation. After that, we
positioned the cuff of a sphygmomanometer in the forearm and inflated the cuff
to at least 50 mmHg above the baseline systolic pressure during 5 minutes to
occlude the artery. We then deflated the cuff, inducing a brief status of
increased flow or reactive hyperemia, and 1 minute later obtained the image of
the FMV, which represents the endothelium-dependent dilatation that occurs due
to nitric oxide production caused by shear stress. We digitalized images during
movement, starting 30 seconds before cuff deflation until 2 minutes later. An
image corresponding to the second rest phase was acquired 15 minutes later. We
then obtained again the Doppler flow of the brachial artery after releasing the
cuff and 15 seconds before deflation, registering the flow speed during
hyperemia. Finally, we measured the endothelium-independent vasodilation by
calculating the vasodilation response 4 minutes after administration of
sublingual isosorbide dinitrate 5 mg.</p><p>We digitalized all steps of the FMV assessments to analyze later the correlations
between the arterial diameter at baseline and the maximum arterial diameters
after dilation, as well as the FMV percentages. This analysis was conducted with
22% of the cohort, and the intraobserver correlations for these measurements
were 0.99, 0.98, and 0.88, respectively, whereas the interobserver correlations
were 0.98, 0.91, and 0.82, respectively. We did not perform evaluations at
different moments, <italic>i.e.</italic> new FMV acquisitions specifically for
this type of analysis.</p></sec><sec><title>Data Analysis</title><p>The sample size was estimated <italic>a priori</italic> to achieve a statistical
power of 90% ( = 5%) to detect an absolute difference of 20% in FMV variation
between the treatment groups (simvastatin 80 and simvastatin 10/ezetimibe;
intergroup comparison). We used the pessimistic premise that the standard
deviation of the delta in each group would be around 15%, resulting in the
requirement of 13 patients in each group.</p><p>The FMV was calculated as the percentage variation in artery diameter after
hyperemia. The effect of the treatment on the endothelial function was measured
primarily by the percentage change in FMV between baseline and after 8 weeks of
treatment. This variable was compared between the two treatment groups with the
Mann-Whitney test. In the intragroup analysis, FMV measurements were compared
separately in each group before and after treatment with the Wilcoxon
signed-rank test. For paired comparison of FMV at all three moments (baseline, 4
weeks, and 8 weeks) we used ANOVA for repeated measures. This analysis was also
used to compare the treatment effects considering all three moments through an
interaction between group and moment. In addition, to assess during follow-up
the occurrence of possible clinical differences between the groups that could
constitute confusion biases, we performed ANOVA for comparison of the clinical
characteristics among the three groups.</p><p>Secondarily, we compared using the Mann-Whitney test the percentage variation in
FMV between baseline and the 8th week in the active treatment groups with those
in the placebo group. In this case, we opted for not comparing simultaneously
the three groups (ANOVA), since this was considered a complementary analysis
that did not concern the main hypothesis of the study. For group comparison at
the intermediate analysis (4th week), the treatment was carried out in a similar
way, since this was a complementary analysis.</p><p>We tested the linear association between the changes in LDL-cholesterol and FMV
results with Spearman's correlation coefficient. We used analysis of covariance
(ANCOVA) to adjust the treatment effect for age. We considered two-tailed
probability values &#x0003c; 0.05 as statistically significant. The results are
presented as mean &#x000b1; standard deviation for continuous variables and as
percentage for categorical variables. Variables not following a normal
distribution are expressed as median and interquartile range (IQR). For
statistical analyses, we used the software Statistical Package for Social
Sciences, version 20 for Windows (SPSS Inc, Chicago, IL, USA).</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Characteristics of the Cohort</title><p>The cohort was characterized by young adult women (43 &#x000b1; 10 years) with
excess weight, evidenced by a BMI of 35 &#x000b1; 5.8 kg/m<sup><xref rid="r2" ref-type="bibr">2</xref></sup>. Mean plasma LDL-cholesterol
levels were slightly elevated (137 &#x000b1; 31 mg/dL), while the median
C-reactive protein level (3.6 mg/L, IQR = 1.7 - 6.7 mg/L) indicated an
exacerbated inflammatory status. As for the endothelial function, the mean FMV
was 8.5% &#x000b1; 4.3%, including reduced and normal FMV values (healthy
patients are considered to have an FMV above 7%).<sup><xref rid="r13" ref-type="bibr">13</xref></sup> A diagnosis of diabetes was present in 8.7% of
the participants, who were all taking metformin. Also, 41% of the participants
had hypertension and were on antihypertensive drugs. None of the participants
had hepatic or renal dysfunction.</p><p>Following randomization, 16 women were allocated to the simvastatin 80 group, 16
to the simvastatin 10/ezetimibe group, and 14 to the placebo group. There were
no significant differences among the treatment groups regarding clinical and
laboratory characteristics or class of antihypertensive drugs (<xref ref-type="table" rid="t1">Table 1</xref>). During follow-up, the clinical
characteristics remained similar among the groups (<xref ref-type="table" rid="t2">Table 2</xref>). The mean FMV results were similar between the
groups simvastatin 80 (8.4% &#x000b1; 4.3%), simvastatin 10/ezetimibe (7.6%
&#x000b1; 3.9%), and placebo (9.8% &#x000b1; 4.5%, p = 0.31).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Comparison of clinical and laboratory characteristics among the treatment
groups</p></caption><table frame="hsides" rules="groups"><colgroup width="20%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Simvastatin 80</th><th align="center" rowspan="1" colspan="1">Simvastatin 10/Ezetimibe</th><th align="center" rowspan="1" colspan="1">Placebo</th><th align="center" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sample</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">41 &#x000b1; 8.6</td><td align="center" rowspan="1" colspan="1">48 &#x000b1; 8.1</td><td align="center" rowspan="1" colspan="1">40 &#x000b1; 12</td><td align="center" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">35 &#x000b1; 4.3</td><td align="center" rowspan="1" colspan="1">36 &#x000b1; 4.4</td><td align="center" rowspan="1" colspan="1">36 &#x000b1; 8.6</td><td align="center" rowspan="1" colspan="1">0.90</td></tr><tr><td align="left" rowspan="1" colspan="1">Waist circumference (cm)</td><td align="center" rowspan="1" colspan="1">107 &#x000b1; 7.6</td><td align="center" rowspan="1" colspan="1">108 &#x000b1; 9.9</td><td align="center" rowspan="1" colspan="1">107 &#x000b1;17</td><td align="center" rowspan="1" colspan="1">0.94</td></tr><tr><td align="left" rowspan="1" colspan="1">Waist/hip</td><td align="center" rowspan="1" colspan="1">0.92 &#x000b1; 0.71</td><td align="center" rowspan="1" colspan="1">0.92 &#x000b1; 0.67</td><td align="center" rowspan="1" colspan="1">0.91 &#x000b1; 0.56</td><td align="center" rowspan="1" colspan="1">0.84</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP (mmHg)</td><td align="center" rowspan="1" colspan="1">133 &#x000b1; 15</td><td align="center" rowspan="1" colspan="1">132 &#x000b1; 18</td><td align="center" rowspan="1" colspan="1">130 &#x000b1; 18</td><td align="center" rowspan="1" colspan="1">0.86</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP (mmHg)</td><td align="center" rowspan="1" colspan="1">85 &#x000b1; 9</td><td align="center" rowspan="1" colspan="1">86 &#x000b1; 13</td><td align="center" rowspan="1" colspan="1">81 &#x000b1; 14</td><td align="center" rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">205 &#x000b1; 29</td><td align="center" rowspan="1" colspan="1">225 &#x000b1; 47</td><td align="center" rowspan="1" colspan="1">206 &#x000b1; 33</td><td align="center" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">49 &#x000b1; 11</td><td align="center" rowspan="1" colspan="1">52 &#x000b1; 12</td><td align="center" rowspan="1" colspan="1">49 &#x000b1; 11</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL-cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">133 &#x000b1; 26</td><td align="center" rowspan="1" colspan="1">149 &#x000b1; 43</td><td align="center" rowspan="1" colspan="1">136 &#x000b1; 27</td><td align="center" rowspan="1" colspan="1">0.50</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides (mg/dL)</td><td align="center" rowspan="1" colspan="1">125 &#x000b1; 51</td><td align="center" rowspan="1" colspan="1">121 &#x000b1; 67</td><td align="center" rowspan="1" colspan="1">115 &#x000b1; 41</td><td align="center" rowspan="1" colspan="1">0.46</td></tr><tr><td align="left" rowspan="1" colspan="1">CRP (mg/dL)</td><td align="center" rowspan="1" colspan="1">3.9 (2.1 &#x02013; 8.1)</td><td align="center" rowspan="1" colspan="1">3.0 (1.8 &#x02013; 5.1)</td><td align="center" rowspan="1" colspan="1">3.3 (1.2 &#x02013; 7.2)</td><td align="center" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood glucose (mg/dL)</td><td align="center" rowspan="1" colspan="1">96 &#x000b1; 12</td><td align="center" rowspan="1" colspan="1">103 &#x000b1; 24</td><td align="center" rowspan="1" colspan="1">94 &#x000b1; 19</td><td align="center" rowspan="1" colspan="1">0.39</td></tr><tr><td align="left" rowspan="1" colspan="1">Urea (mg/dL)</td><td align="center" rowspan="1" colspan="1">29 &#x000b1; 7.3</td><td align="center" rowspan="1" colspan="1">29 &#x000b1; 8.3</td><td align="center" rowspan="1" colspan="1">26 &#x000b1; 6</td><td align="center" rowspan="1" colspan="1">0.42</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (mg/dL)</td><td align="center" rowspan="1" colspan="1">0.83 &#x000b1; 0.11</td><td align="center" rowspan="1" colspan="1">0.79 &#x000b1; 0.12</td><td align="center" rowspan="1" colspan="1">0.85 &#x000b1; 0.18</td><td align="center" rowspan="1" colspan="1">0.55</td></tr><tr><td align="left" rowspan="1" colspan="1">AST (U/L)</td><td align="center" rowspan="1" colspan="1">18 &#x000b1; 5.1</td><td align="center" rowspan="1" colspan="1">20 &#x000b1; 4.6</td><td align="center" rowspan="1" colspan="1">20 &#x000b1; 11</td><td align="center" rowspan="1" colspan="1">0.71</td></tr><tr><td align="left" rowspan="1" colspan="1">ALT (U/L)</td><td align="center" rowspan="1" colspan="1">18 &#x000b1; 5.1</td><td align="center" rowspan="1" colspan="1">20 &#x000b1; 4.6</td><td align="center" rowspan="1" colspan="1">20 &#x000b1; 11</td><td align="center" rowspan="1" colspan="1">0.71</td></tr><tr><td align="left" rowspan="1" colspan="1">GGT (U/L)</td><td align="center" rowspan="1" colspan="1">32 &#x000b1; 11.74</td><td align="center" rowspan="1" colspan="1">42 &#x000b1; 22.99</td><td align="center" rowspan="1" colspan="1">42 &#x000b1; 23.70</td><td align="center" rowspan="1" colspan="1">0.27</td></tr><tr><td align="left" rowspan="1" colspan="1">CPK (mg/dL)</td><td align="center" rowspan="1" colspan="1">123 &#x000b1; 60</td><td align="center" rowspan="1" colspan="1">168 &#x000b1; 88</td><td align="center" rowspan="1" colspan="1">109 &#x000b1; 62</td><td align="center" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">5 (31%)</td><td align="center" rowspan="1" colspan="1">6 (38%)</td><td align="center" rowspan="1" colspan="1">8 (57%)</td><td align="center" rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" rowspan="1" colspan="1">ACEi</td><td align="center" rowspan="1" colspan="1">2 (13%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">4 (29%)</td><td align="center" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">ARB</td><td align="center" rowspan="1" colspan="1">1 (6.3%)</td><td align="center" rowspan="1" colspan="1">2 (13%)</td><td align="center" rowspan="1" colspan="1">2 (14%)</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Menopause</td><td align="center" rowspan="1" colspan="1">1 (6.3%)</td><td align="center" rowspan="1" colspan="1">4 (25%)</td><td align="center" rowspan="1" colspan="1">2 (14%)</td><td align="center" rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking</td><td align="center" rowspan="1" colspan="1">0 (6.3%)</td><td align="center" rowspan="1" colspan="1">1 (6.3%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" rowspan="1" colspan="1">Sedentary lifestyle</td><td align="center" rowspan="1" colspan="1">11 (69%)</td><td align="center" rowspan="1" colspan="1">8 (50%)</td><td align="center" rowspan="1" colspan="1">8 (57%)</td><td align="center" rowspan="1" colspan="1">0.55</td></tr><tr><td align="left" rowspan="1" colspan="1">Low-calorie diet</td><td align="center" rowspan="1" colspan="1">6 (38%)</td><td align="center" rowspan="1" colspan="1">7 (44%)</td><td align="center" rowspan="1" colspan="1">6 (43%)</td><td align="center" rowspan="1" colspan="1">0.93</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">1 (6.3%)</td><td align="center" rowspan="1" colspan="1">3 (21%)</td><td align="center" rowspan="1" colspan="1">0.10</td></tr><tr><td align="left" rowspan="1" colspan="1">Coffee consumption</td><td align="center" rowspan="1" colspan="1">14 (88%)</td><td align="center" rowspan="1" colspan="1">14 (88%)</td><td align="center" rowspan="1" colspan="1">12 (86%)</td><td align="center" rowspan="1" colspan="1">0.99</td></tr><tr><td align="left" rowspan="1" colspan="1">FMV</td><td align="center" rowspan="1" colspan="1">8.4% &#x000b1; 4.3%</td><td align="center" rowspan="1" colspan="1">7.6% &#x000b1; 3.9%</td><td align="center" rowspan="1" colspan="1">9.8% &#x000b1; 4.5%</td><td align="center" rowspan="1" colspan="1">0.31</td></tr></tbody></table><table-wrap-foot><fn id="TFN01"><p>BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic
blood pressure; HDL: High-density lipoprotein; LDL: low-density
lipoprotein; CRP: C-reactive protein; AST: aspartate
aminotransferase; ALT: alanine aminotransferase; GGT: Gamma
glutamyltransferase; CPK: creatine phosphokinase; ACEi:
angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor
blocker; FMV: flow-mediated vasodilation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Comparison of the clinical characteristics in the three groups during
follow-up</p></caption><table frame="hsides" rules="groups"><colgroup width="16%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="2" align="left" colspan="1">Characteristics</th><th rowspan="2" align="center" colspan="1">Follow-up (weeks)</th><th style="border-bottom-width:thin;border-bottom-style:solid" colspan="4" align="center" rowspan="1">Treatment groups</th></tr><tr><th align="center" rowspan="1" colspan="1">Simvastatin 80</th><th align="center" rowspan="1" colspan="1">Simvastatin 10/Ezetimibe</th><th align="center" rowspan="1" colspan="1">Placebo</th><th align="center" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">4<break/>8</td><td align="center" rowspan="1" colspan="1">35 &#x000b1; 4.3<break/>34 &#x000b1; 4.4</td><td align="center" rowspan="1" colspan="1">35 &#x000b1; 4.4<break/>35 &#x000b1; 4.3</td><td align="center" rowspan="1" colspan="1">35 &#x000b1; 6.6<break/>36 &#x000b1; 9.3</td><td align="center" rowspan="1" colspan="1">0.87<break/>0.77</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP (mmHg)</td><td align="center" rowspan="1" colspan="1">4<break/>8</td><td align="center" rowspan="1" colspan="1">133 &#x000b1; 13.5<break/>133 &#x000b1; 14.5</td><td align="center" rowspan="1" colspan="1">132 &#x000b1; 15.3<break/>133 &#x000b1; 15.5</td><td align="center" rowspan="1" colspan="1">130 &#x000b1; 15.71<break/>32 &#x000b1; 15.1</td><td align="center" rowspan="1" colspan="1">0.84<break/>0.82</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP (mmHg)</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">86 &#x000b1; 7.3<break/>84 &#x000b1; 9.4</td><td align="center" rowspan="1" colspan="1">83 &#x000b1; 9.3<break/>84 &#x000b1; 9.4</td><td align="center" rowspan="1" colspan="1">81 &#x000b1; 12<break/>81 &#x000b1; 12</td><td align="center" rowspan="1" colspan="1">0.39<break/>0.49</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">4<break/>8</td><td align="center" rowspan="1" colspan="1">49 &#x000b1; 9.8<break/>51 &#x000b1; 12</td><td align="center" rowspan="1" colspan="1">53 &#x000b1; 14<break/>52 &#x000b1; 13</td><td align="center" rowspan="1" colspan="1">52 &#x000b1; 14<break/>50 &#x000b1; 8</td><td align="center" rowspan="1" colspan="1">0.76<break/>0.89</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides (mg/dL)</td><td align="center" rowspan="1" colspan="1">4<break/>8</td><td align="center" rowspan="1" colspan="1">91 &#x000b1; 29<break/>99 &#x000b1; 39</td><td align="center" rowspan="1" colspan="1">124 &#x000b1; 60<break/>122 &#x000b1; 73</td><td align="center" rowspan="1" colspan="1">132 &#x000b1; 38<break/>127 &#x000b1; 52</td><td align="center" rowspan="1" colspan="1">0.30<break/>0.34</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood glucose (mg/dL)</td><td align="center" rowspan="1" colspan="1">4<break/>8</td><td align="center" rowspan="1" colspan="1">93 &#x000b1; 11<break/>95 &#x000b1; 10</td><td align="center" rowspan="1" colspan="1">102 &#x000b1; 22<break/>102 &#x000b1; 18</td><td align="center" rowspan="1" colspan="1">111 &#x000b1; 54<break/>103 &#x000b1; 32</td><td align="center" rowspan="1" colspan="1">0.28<break/>0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">Urea (mg/dL)</td><td align="center" rowspan="1" colspan="1">4<break/>8</td><td align="center" rowspan="1" colspan="1">31 &#x000b1; 5.0<break/>29 &#x000b1; 6.3</td><td align="center" rowspan="1" colspan="1">28 &#x000b1; 4.7<break/>28 &#x000b1; 6.4</td><td align="center" rowspan="1" colspan="1">28 &#x000b1; 4.7<break/>27 &#x000b1; 5.3</td><td align="center" rowspan="1" colspan="1">0.30<break/>0.43</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (mg/dL)</td><td align="center" rowspan="1" colspan="1">4<break/>8</td><td align="center" rowspan="1" colspan="1">0.84 &#x000b1; 0.14<break/>0.82 &#x000b1; 0.12</td><td align="center" rowspan="1" colspan="1">0.85 &#x000b1; 0.15<break/>0.80 &#x000b1; 0.12</td><td align="center" rowspan="1" colspan="1">0.78 &#x000b1; 0.12<break/>0.87 &#x000b1; 0.19</td><td align="center" rowspan="1" colspan="1">0.42<break/>0.37</td></tr><tr><td align="left" rowspan="1" colspan="1">AST (U/L)</td><td align="center" rowspan="1" colspan="1">4<break/>8</td><td align="center" rowspan="1" colspan="1">17 &#x000b1; 4<break/>19 &#x000b1; 5</td><td align="center" rowspan="1" colspan="1">22 &#x000b1; 9<break/>23 &#x000b1; 10</td><td align="center" rowspan="1" colspan="1">17 &#x000b1; 7<break/>18 &#x000b1; 5</td><td align="center" rowspan="1" colspan="1">0.17<break/>0.17</td></tr><tr><td align="left" rowspan="1" colspan="1">ALT (U/L)</td><td align="center" rowspan="1" colspan="1">4<break/>8</td><td align="center" rowspan="1" colspan="1">17 &#x000b1; 6<break/>21 &#x000b1; 8</td><td align="center" rowspan="1" colspan="1">26 &#x000b1; 15<break/>25 &#x000b1; 12</td><td align="center" rowspan="1" colspan="1">17 &#x000b1; 10<break/>18 &#x000b1; 10</td><td align="center" rowspan="1" colspan="1">0.12<break/>0.17</td></tr><tr><td align="left" rowspan="1" colspan="1">GGT (U/L)</td><td align="center" rowspan="1" colspan="1">4<break/>8</td><td align="center" rowspan="1" colspan="1">31 &#x000b1; 9.3<break/>32 &#x000b1; 11.1</td><td align="center" rowspan="1" colspan="1">41 &#x000b1; 18.8<break/>38 &#x000b1; 15.3</td><td align="center" rowspan="1" colspan="1">44 &#x000b1; 30.8<break/>42 &#x000b1; 33.1</td><td align="center" rowspan="1" colspan="1">0.32<break/>0.53</td></tr><tr><td align="left" rowspan="1" colspan="1">CPK (mg/dL)</td><td align="center" rowspan="1" colspan="1">4<break/>8</td><td align="center" rowspan="1" colspan="1">136 &#x000b1;64<break/>155 &#x000b1; 84</td><td align="center" rowspan="1" colspan="1">185 &#x000b1; 127<break/>195 &#x000b1; 118</td><td align="center" rowspan="1" colspan="1">103 &#x000b1; 60<break/>120 &#x000b1; 67</td><td align="center" rowspan="1" colspan="1">0.12<break/>0.10</td></tr><tr><td align="left" rowspan="1" colspan="1">CRP (mg/dL)</td><td align="center" rowspan="1" colspan="1">4<break/>8</td><td align="center" rowspan="1" colspan="1">3.3 (2.1 &#x02013; 6.4)<break/>2.9 (1.9 &#x02013; 8.3)</td><td align="center" rowspan="1" colspan="1">2.0 (1.7 &#x02013; 4.2)<break/>2.0 (1.6 &#x02013; 4.2)</td><td align="center" rowspan="1" colspan="1">4.0 (2.4 &#x02013; 8.2)<break/>4.4 (2.7 &#x02013; 8.3)</td><td align="center" rowspan="1" colspan="1">0.19<break/>0.43</td></tr></tbody></table><table-wrap-foot><fn id="TFN02"><p>BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic
blood pressure; HDL: high-density lipoprotein; AST: aspartate
aminotransferase; ALT: alanine aminotransferase; GGT: gamma
glutamyltransferase; CPK: Creatine phosphokinase; CRP: C-reactive
protein.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Antilipidemic Effect of the Treatments</title><p>During the 8 weeks of the study, there were no treatment interruptions, and the
adherence was complete and identical in all three groups. No side effects
requiring treatment suspension were recorded. There were minor symptoms, of
which the most frequent was headache (one case in the simvastatin 80 group, one
case in the simvastatin 10/ezetimibe group, and three cases in the placebo
group), followed by leg pain (one case in the simvastatin 80 group and one case
in the simvastatin 10/ezetimibe group), and vomiting (one case in the
simvastatin 10/ezetimibe group).</p><p>After 8 weeks of active treatment, there was a significant reduction in
LDL-cholesterol levels, which was similar between the groups simvastatin 80 (27%
&#x000b1; 31%) and simvastatin 10/ezetimibe (30% &#x000b1; 29%, p = 0.75). The
absolute reduction was 36 &#x000b1; 45 mg/dL in the simvastatin 80 group and 45
&#x000b1; 36 mg/dL in the simvastatin 10/ezetimibe group (p = 0.57). There was no
reduction in LDL-cholesterol levels in the placebo group (<xref ref-type="table" rid="t3">Table 3</xref> and <xref ref-type="fig" rid="f2">Figure
2</xref>).</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Effect of the treatments on lipid and metabolic profiles in the three
groups at 4 and 8 weeks</p></caption><table frame="hsides" rules="groups"><colgroup width="16%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">8 Weeks</th><th align="center" rowspan="1" colspan="1">p</th><th align="center" rowspan="1" colspan="1">4 Weeks</th><th align="center" rowspan="1" colspan="1">p (4 <italic>versus</italic>8 weeks)</th></tr></thead><tbody><tr><td colspan="6" align="left" rowspan="1"><bold>Simvastatin 80</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">LDL-cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">133 &#x000b1; 26</td><td align="center" rowspan="1" colspan="1">95 &#x000b1; 44</td><td align="center" rowspan="1" colspan="1">0.006</td><td align="center" rowspan="1" colspan="1">72 &#x000b1; 23</td><td align="center" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">205 &#x000b1; 29</td><td align="center" rowspan="1" colspan="1">166 &#x000b1; 48</td><td align="center" rowspan="1" colspan="1">0.007</td><td align="center" rowspan="1" colspan="1">141 &#x000b1; 26</td><td align="center" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">49 &#x000b1; 11</td><td align="center" rowspan="1" colspan="1">51 &#x000b1; 12</td><td align="center" rowspan="1" colspan="1">0.48</td><td align="center" rowspan="1" colspan="1">49 &#x000b1; 9.8</td><td align="center" rowspan="1" colspan="1">0.97</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides (mg/dL)</td><td align="center" rowspan="1" colspan="1">125 &#x000b1; 51</td><td align="center" rowspan="1" colspan="1">99 &#x000b1; 39</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">91 &#x000b1; 29</td><td align="center" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood glucose (mg/dL)</td><td align="center" rowspan="1" colspan="1">96 &#x000b1; 12</td><td align="center" rowspan="1" colspan="1">95 &#x000b1; 10</td><td align="center" rowspan="1" colspan="1">0.88</td><td align="center" rowspan="1" colspan="1">93 &#x000b1; 11</td><td align="center" rowspan="1" colspan="1">0.28</td></tr><tr><td colspan="6" align="left" rowspan="1"><bold>Simvastatin
10/Ezetimibe</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">LDL-cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">149 &#x000b1; 43</td><td align="center" rowspan="1" colspan="1">100 &#x000b1; 45</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td><td align="center" rowspan="1" colspan="1">97 &#x000b1; 49</td><td align="center" rowspan="1" colspan="1">0.90</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">226 &#x000b1; 51</td><td align="center" rowspan="1" colspan="1">176 &#x000b1; 54</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td><td align="center" rowspan="1" colspan="1">169 &#x000b1; 52</td><td align="center" rowspan="1" colspan="1">0.83</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">54 &#x000b1; 12</td><td align="center" rowspan="1" colspan="1">52 &#x000b1; 13</td><td align="center" rowspan="1" colspan="1">0.98</td><td align="center" rowspan="1" colspan="1">53 &#x000b1; 14</td><td align="center" rowspan="1" colspan="1">0.39</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides (mg/dL)</td><td align="center" rowspan="1" colspan="1">121 &#x000b1; 67</td><td align="center" rowspan="1" colspan="1">122 &#x000b1; 73</td><td align="center" rowspan="1" colspan="1">0.08</td><td align="center" rowspan="1" colspan="1">124 &#x000b1; 60</td><td align="center" rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood glucose (mg/dL)</td><td align="center" rowspan="1" colspan="1">103 &#x000b1; 24</td><td align="center" rowspan="1" colspan="1">102 &#x000b1; 18</td><td align="center" rowspan="1" colspan="1">0.28</td><td align="center" rowspan="1" colspan="1">102 &#x000b1; 22</td><td align="center" rowspan="1" colspan="1">0.65</td></tr><tr><td colspan="6" align="left" rowspan="1"><bold>Placebo</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">LDL-cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">136 &#x000b1; 27</td><td align="center" rowspan="1" colspan="1">137 &#x000b1; 29</td><td align="center" rowspan="1" colspan="1">0.80</td><td align="center" rowspan="1" colspan="1">123 &#x000b1; 30</td><td align="center" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">206 &#x000b1; 33</td><td align="center" rowspan="1" colspan="1">212 &#x000b1; 31</td><td align="center" rowspan="1" colspan="1">0.79</td><td align="center" rowspan="1" colspan="1">201 &#x000b1; 35</td><td align="center" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">49 &#x000b1; 11</td><td align="center" rowspan="1" colspan="1">50 &#x000b1; 8</td><td align="center" rowspan="1" colspan="1">0.39</td><td align="center" rowspan="1" colspan="1">52 &#x000b1; 14</td><td align="center" rowspan="1" colspan="1">0.50</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides (mg/dL)</td><td align="center" rowspan="1" colspan="1">115 &#x000b1; 41</td><td align="center" rowspan="1" colspan="1">127 &#x000b1; 52</td><td align="center" rowspan="1" colspan="1">0.27</td><td align="center" rowspan="1" colspan="1">132 &#x000b1; 38</td><td align="center" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood glucose (mg/dL)</td><td align="center" rowspan="1" colspan="1">94 &#x000b1; 19</td><td align="center" rowspan="1" colspan="1">103 &#x000b1; 32</td><td align="center" rowspan="1" colspan="1">0.06</td><td align="center" rowspan="1" colspan="1">111 &#x000b1; 54</td><td align="center" rowspan="1" colspan="1">0.40</td></tr></tbody></table><table-wrap-foot><fn id="TFN03"><p>LDL: low-density lipoprotein; HDL: high-density lipoprotein.</p></fn></table-wrap-foot></table-wrap><p><fig id="f2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Effect of the treatments on LDL-cholesterol, showing a significant
reduction of this lipoprotein in the active groups.</p></caption><graphic xlink:href="abc-106-04-0279-g02"/></fig>
</p><p>The reduction in LDL-cholesterol level was already present in the assessment
performed at 4 weeks of treatment, which did not differ from that performed at
the 8th week in the simvastatin 80 group (p = 0.15) or in the simvastatin
10/ezetimibe group (p = 0.90).</p><p>There was no significant variation in plasma levels of HDL-cholesterol or
triglycerides in any of the three treatment groups, except for a reduction in
triglyceride levels in the simvastatin 80 group. Similarly, blood glucose levels
remained unchanged. Liver enzymes, C-reactive protein, CPK, and weight did not
change significantly during treatment. Exceptions to that were increases in CPK
level in the simvastatin 80 group, which occurred without clinical complaints or
values considered of risk, and ALT in the simvastatin 10/ezetimibe group (<xref ref-type="table" rid="t4">Table 4</xref>).</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Effect of the treatments on weight and biochemical characteristics</p></caption><table frame="hsides" rules="groups"><colgroup width="16%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">4 Weeks</th><th align="center" rowspan="1" colspan="1">p</th><th align="center" rowspan="1" colspan="1">8 Weeks</th><th align="center" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td colspan="6" align="left" rowspan="1"><bold>Simvastatin 80</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">35 &#x000b1; 4.3</td><td align="center" rowspan="1" colspan="1">35 &#x000b1; 4.3</td><td align="center" rowspan="1" colspan="1">0.51</td><td align="center" rowspan="1" colspan="1">34 &#x000b1; 4.4</td><td align="center" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" rowspan="1" colspan="1">Aspartate aminotransferase (U/L)</td><td align="center" rowspan="1" colspan="1">18 &#x000b1; 5.1</td><td align="center" rowspan="1" colspan="1">17 &#x000b1; 4</td><td align="center" rowspan="1" colspan="1">0.73</td><td align="center" rowspan="1" colspan="1">19 &#x000b1; 5</td><td align="center" rowspan="1" colspan="1">0.50</td></tr><tr><td align="left" rowspan="1" colspan="1">Alanine aminotransferase (U/L)</td><td align="center" rowspan="1" colspan="1">18 &#x000b1; 5.1</td><td align="center" rowspan="1" colspan="1">17 &#x000b1; 6</td><td align="center" rowspan="1" colspan="1">0.90</td><td align="center" rowspan="1" colspan="1">21 &#x000b1; 8</td><td align="center" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatine phosphokinase (mg/dL)</td><td align="center" rowspan="1" colspan="1">123 &#x000b1; 60</td><td align="center" rowspan="1" colspan="1">136 &#x000b1;64</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">155 &#x000b1; 84</td><td align="center" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">CRP (mg/dL)</td><td align="center" rowspan="1" colspan="1">3.9 (2.1 - 8.1)</td><td align="center" rowspan="1" colspan="1">3.3 (2.1 - 6.4)</td><td align="center" rowspan="1" colspan="1">0.14</td><td align="center" rowspan="1" colspan="1">2.9 (1.9 - 8.3)</td><td align="center" rowspan="1" colspan="1">0.65</td></tr><tr><td colspan="6" align="left" rowspan="1"><bold>Simvastatin
10/Ezetimibe</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">36 &#x000b1; 4.4</td><td align="center" rowspan="1" colspan="1">35 &#x000b1; 4.4</td><td align="center" rowspan="1" colspan="1">0.63</td><td align="center" rowspan="1" colspan="1">35 &#x000b1; 4.3</td><td align="center" rowspan="1" colspan="1">0.27</td></tr><tr><td align="left" rowspan="1" colspan="1">Aspartate aminotransferase (U/L)</td><td align="center" rowspan="1" colspan="1">20 &#x000b1; 4.6</td><td align="center" rowspan="1" colspan="1">22 &#x000b1; 9</td><td align="center" rowspan="1" colspan="1">0.42</td><td align="center" rowspan="1" colspan="1">23 &#x000b1; 10</td><td align="center" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" rowspan="1" colspan="1">Alanine aminotransferase (U/L)</td><td align="center" rowspan="1" colspan="1">20 &#x000b1; 4.6</td><td align="center" rowspan="1" colspan="1">26 &#x000b1; 15</td><td align="center" rowspan="1" colspan="1">0.21</td><td align="center" rowspan="1" colspan="1">25 &#x000b1; 12</td><td align="center" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatine phosphokinase (mg/dL)</td><td align="center" rowspan="1" colspan="1">168 &#x000b1; 88</td><td align="center" rowspan="1" colspan="1">185 &#x000b1; 127</td><td align="center" rowspan="1" colspan="1">0.30</td><td align="center" rowspan="1" colspan="1">195 &#x000b1; 118</td><td align="center" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">CRP (mg/dL)</td><td align="center" rowspan="1" colspan="1">3.0 (1.8 &#x02013; 5.1)</td><td align="center" rowspan="1" colspan="1">2.0 (1.7 &#x02013; 4.2)</td><td align="center" rowspan="1" colspan="1">0.55</td><td align="center" rowspan="1" colspan="1">2.0 (1.6 &#x02013; 4.2)</td><td align="center" rowspan="1" colspan="1">0.66</td></tr><tr><td colspan="6" align="left" rowspan="1"><bold>Placebo</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">36 &#x000b1; 8.6</td><td align="center" rowspan="1" colspan="1">35 &#x000b1; 6.6</td><td align="center" rowspan="1" colspan="1">0.23</td><td align="center" rowspan="1" colspan="1">36 &#x000b1; 9.4</td><td align="center" rowspan="1" colspan="1">0.81</td></tr><tr><td align="left" rowspan="1" colspan="1">Aspartate aminotransferase (U/L)</td><td align="center" rowspan="1" colspan="1">20 &#x000b1; 11</td><td align="center" rowspan="1" colspan="1">17 &#x000b1; 7</td><td align="center" rowspan="1" colspan="1">0.59</td><td align="center" rowspan="1" colspan="1">18 &#x000b1; 5</td><td align="center" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">Alanine aminotransferase (U/L)</td><td align="center" rowspan="1" colspan="1">20 &#x000b1; 11</td><td align="center" rowspan="1" colspan="1">17 &#x000b1; 10</td><td align="center" rowspan="1" colspan="1">0.20</td><td align="center" rowspan="1" colspan="1">18 &#x000b1; 10</td><td align="center" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatine phosphokinase (mg/dL)</td><td align="center" rowspan="1" colspan="1">109 &#x000b1; 62</td><td align="center" rowspan="1" colspan="1">103 &#x000b1; 60</td><td align="center" rowspan="1" colspan="1">0.17</td><td align="center" rowspan="1" colspan="1">120 &#x000b1; 67</td><td align="center" rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" rowspan="1" colspan="1">CRP (mg/dL)</td><td align="center" rowspan="1" colspan="1">3.3 (1.2 &#x02013; 7.2)</td><td align="center" rowspan="1" colspan="1">4.0 (2.4 &#x02013; 8.2)</td><td align="center" rowspan="1" colspan="1">0.43</td><td align="center" rowspan="1" colspan="1">4.4 (2.7 &#x02013; 8.3)</td><td align="center" rowspan="1" colspan="1">0.11</td></tr></tbody></table><table-wrap-foot><fn id="TFN04"><p>CRP: C-reactive protein (median and interquartile range).</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Effect of the Treatments on Arterial Flow-Mediated Vasodilation</title><p>The simvastatin 80 group presented an increase in FMV from 8.4% &#x000b1; 4.3% to
11% &#x000b1; 4.2% after 8 weeks of treatment (p = 0.02). Similarly, the
simvastatin 10/ezetimibe group showed improvement in vasodilation, from 7.3%
&#x000b1; 3.9% to 12% &#x000b1; 4.4% (p = 0.001). In relative terms, the variation
in arterial vasodilation had a median of +39% (IQR = 2.2% to 105%) in the
simvastatin 80 group, which was similar to +41% (IQR = 13% to 227%) in the
simvastatin 10/ezetimibe group (p = 0.36). This comparison remained
nonsignificant after adjustment for the difference in age between these two
groups (ANCOVA, p = 0.30). The placebo group presented a minimal variation in
arterial vasodilation, with a median of +6.2% (IQR = - 6.6% to 56%), without
statistical significance in the comparison between the baseline measurement and
that performed at the 8th week (p = 0.28; <xref ref-type="fig" rid="f3">Figure
3</xref> and <xref ref-type="table" rid="t5">Table 5</xref>). When we
performed a paired comparison of the three moments of evaluation (baseline, 4
weeks, and 8 weeks) with ANOVA for repeated measures, the simvastatin 80 (p =
0.045) and simvastatin 10/ezetimibe (p = 0.001) groups showed significant
variations, which was different from the placebo group (p = 0.25). In this
analysis, there was no interaction between group and moment when only the active
treatments were considered (p = 0.30), indicating a similar variation between
these two groups.</p><table-wrap id="t5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Effect of the three treatments on flow-mediated vasodilation</p></caption><table frame="hsides" rules="groups"><colgroup width="16%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">8 Weeks</th><th align="center" rowspan="1" colspan="1">p</th><th align="center" rowspan="1" colspan="1">4 Weeks</th><th align="center" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td colspan="6" align="left" rowspan="1"><bold>Simvastatin 80</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">FMV (%)</td><td align="center" rowspan="1" colspan="1">8.4 &#x000b1; 4.3</td><td align="center" rowspan="1" colspan="1">11 &#x000b1; 4.2</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">8.6 &#x000b1; 3.6</td><td align="center" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">FMV variation</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">+ 39% (2.2% &#x02013; 105%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">+ 27% (-13% &#x02013; 63%)</td><td align="center" rowspan="1" colspan="1">0.09</td></tr><tr><td colspan="6" align="left" rowspan="1"><bold>Simvastatin
10/Ezetimibe</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">FMV (%)</td><td align="center" rowspan="1" colspan="1">7.3 &#x000b1; 3.9</td><td align="center" rowspan="1" colspan="1">12 &#x000b1; 4.4</td><td align="center" rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">9.1 &#x000b1; 4.3</td><td align="center" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">FMV variation</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">+ 41% (13% &#x02013; 227%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">+ 25% (-4% &#x02013; 92%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td colspan="6" align="left" rowspan="1"><bold>Placebo</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">FMV (%)</td><td align="center" rowspan="1" colspan="1">9.8 &#x000b1; 4.5</td><td align="center" rowspan="1" colspan="1">10 &#x000b1; 4</td><td align="center" rowspan="1" colspan="1">0.28</td><td align="center" rowspan="1" colspan="1">11 &#x000b1; 2.2</td><td align="center" rowspan="1" colspan="1">0.93</td></tr><tr><td align="left" rowspan="1" colspan="1">FMV variation</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">+ 9% (-6.6% &#x02013; 56%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">+13% (-8% &#x02013; 31%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN05"><p>Parentheses - 95% confidence interval. FMV: brachial artery
flow-mediated vasodilation.</p></fn></table-wrap-foot></table-wrap><p><fig id="f3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Variation in flow-mediated vasodilation, indicating an increase in
the two active groups. Panel A: Line graph showing the variation in
vasodilation at 4 and 8 weeks of treatment; Panel B: Bar graph
showing the percentage of variation in vasodilation from baseline to
the 8th week.</p></caption><graphic xlink:href="abc-106-04-0279-g03"/></fig>
</p><p>The active groups showed no differences in the variation in
endothelium-independent vasodilation mediated by nitrate.</p><p>Unlike the effect on LDL-cholesterol, 4 weeks of treatment were not sufficient to
obtain an impact on the arterial FMV comparable to that obtained at the end of 8
weeks, although a trend of improvement in vasodilation was already observed in
this interim assessment. This improvement was represented by a median of +27%
(IQR = - 13% to 63%, p = 0.09) in the simvastatin 80 group and +25% (IQR = - 4%
to 92%, p = 0.03) in the simvastatin 10/ezetimibe group.</p><p>There was a correlation (r = - 0.33, p = 0.03) between the variations in
LDL-cholesterol and FMV in a combined analysis of the studied population.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The present study suggests that the improvement in endothelial function promoted by
statin therapy depends primarily on the drug's hypolipidemic effect, without
evidence of a pleiotropic action. The pleiotropic hypothesis was tested with
different doses of simvastatin (80 mg <italic>versus</italic> 10 mg) under the
assumption that a dose-response gradient would occur if this mechanism were present.
In order to avoid the degree of reduction in LDL-cholesterol as a confounding
factor, ezetimibe was associated to simvastatin in the low simvastatin dose group,
providing the same lipid-lowering effect as the high-dose group. When we observed
that both therapies had the same benefit on the endothelial function, we inferred
that the dose-response gradient was absent.</p><p>In addition to the main result, some secondary findings deserve further discussion.
First, the presence of a placebo group in which the endothelial function remained
unchanged assures us that the improvement observed with the active treatment in both
groups was not due to a phenomenon of regression to the mean. Second, the negative
correlation between the reduction in LDL-cholesterol and the improvement in
endothelial function represents additional information in favor of the
lipid-lowering mechanism, even though it was a weak correlation and that this
analysis, as it is well known, is mainly of exploratory nature and does not show
causality. Third, we observed that the positive influence on the endothelial
function occurs progressively with the length of exposure, since the late results (8
weeks) were better than the early results (4 weeks), despite the fact that the nadir
in LDL-cholesterol levels was achieved at 4 weeks of treatment. Regarding the
anti-inflammatory mechanism, the treatments were unable to promote a reduction in
C-reactive protein levels in any of the groups, which makes it less likely to be an
additional mechanism of improvement in endothelial function.</p><p>The lack of differences in clinical characteristics among the groups, both at
baseline (promoted by the randomization process), and during follow-up (confirmed by
intergroup comparisons at 4 and 8 weeks) assured the control of possible confounding
variables that could have influenced the comparative results of the outcome
variable. The methodological care adopted in this study, especially that regarding
the FMV analysis, also contributed to the internal validation process.</p><p>The recent study of Westerink et al.<sup><xref rid="r14" ref-type="bibr">14</xref></sup> is in line with our results. In this study, the authors
demonstrated a similar impact on the endothelium of simvastatin at a high dose
<italic>versus</italic> low dose associated with ezetimibe in subjects with
metabolic syndrome, as previously reported by Settergren et al.<sup><xref rid="r15" ref-type="bibr">15</xref></sup> as well in patients with diabetes
or coronary disease. In contrast, Liu et al.<sup><xref rid="r16" ref-type="bibr">16</xref></sup> only obtained improvement in FMV with a higher dose of
simvastatin and suggested the occurrence of pleiotropic benefits of the statins
based on results obtained at 4 weeks. Their option to only observe for a short
period of time may have precluded the observation of effects requiring longer
treatment duration.</p><p>Some limitations of this study deserve recognition. The method to measure FMV
followed all the steps of the protocol recommended by the International Brachial
Artery Reactivity Task Force<sup><xref rid="r12" ref-type="bibr">12</xref></sup>.
However, the method has an inherent large variability of measurements influenced by
several external factors. This variability may be a limiting factor to reproduce the
FMV findings and, consequently, their interpretation. The wider circumferences of
the arms of obese women could have led to technical challenges in the measurements.
However, this was not an interfering factor in this study since the cuff of the
sphygmomanometer was positioned in the forearm, which has a shorter circumference
than the arm, leaving a larger area for identification of the brachial artery when
the transducer was positioned on the arm. Although the automated technique is more
robust and accurate,<sup><xref rid="r17" ref-type="bibr">17</xref></sup> the manual
technique used in this study is also reliable and considered feasible to diagnose
and monitor the endothelial function.<sup><xref rid="r18" ref-type="bibr">18</xref></sup></p><p>The study was performed with a small sample, which only consisted of women with
excess weight from a single outpatient clinic. However, since this is a small study,
it justifies the option for homogenizing the sample and including only women. The
selection of women with excess weight had the purpose of including a group more
predisposed to impaired endothelial function,<sup><xref rid="r19" ref-type="bibr">19</xref></sup> favoring the possibility to observe a corrective effect of
the therapy. Although the choice of this type of population is justifiable, we must
recognize that it reduces the generalization of the study to the overall population.
We must also remember that this study has a surrogate outcome (purely mechanistic
objective) that should not be interpreted as evidence that the clinical effect of
the two therapies is similar. Another limitation is related to the low statistical
power and refers to the fact that to avoid detecting differences among the variables
we would need a very large sample, which would make the study unfeasible. Regarding
the analyzes of the deltas in the general variations (including FMV and
LDL-cholesterol), we found no difference among the treatments. These findings may
have been influenced by a large measurement variability, hindering the statistical
analysis.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>In conclusion, the present randomized clinical study showed that the most probable
mechanism of improvement in endothelial function obtained with statins is the
decrease in LDL-cholesterol, independent of the dose of statin used. In this
context, the pleiotropic effects of statins have lower relevance.</p></sec></body><back><fn-group><fn fn-type="conflict"><p><bold>Potential Conflict of Interest</bold></p><p>No potential conflict of interest relevant to this article was reported.</p></fn><fn fn-type="supported-by"><p><bold>Sources of Funding</bold></p><p>This study was funded by FAPESB.</p></fn><fn fn-type="other"><p><bold>Study Association</bold></p><p>This article is part of the thesis of Doctoral submitted by Maristela Magnavita
Oliveira Garcia , from Escola Bahiana de Medicina e Sa&#x000fa;de
P&#x000fa;blica.</p></fn></fn-group><ref-list><title>References</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fonseca</surname><given-names>FA</given-names></name><name><surname>Izar</surname><given-names>MC</given-names></name></person-group><article-title>Primary prevention of vascular events in patients with high
levels of C-reactive protein: the JUPITER study</article-title><source>Expert Rev Cardiovasc Ther</source><year>2009</year><volume>7</volume><issue>9</issue><fpage>1041</fpage><lpage>1056</lpage><pub-id pub-id-type="pmid">19764857</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><article-title>Randomised trial of cholesterol lowering in 4444 patients with
coronary heart disease: the Scandinavian Simvastatin Survival Study
(4S)</article-title><source>Lancet</source><year>1994</year><volume>344</volume><issue>8934</issue><fpage>1383</fpage><lpage>1389</lpage><pub-id pub-id-type="pmid">7968073</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Endo</surname><given-names>A</given-names></name></person-group><article-title>The discovery and development of HMG-CoA reductase inhibitors.
1992</article-title><source>Atheroscler Suppl</source><year>2004</year><volume>5</volume><issue>3</issue><fpage>67</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">15531278</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaughan</surname><given-names>CJ</given-names></name><name><surname>Murphy</surname><given-names>MB</given-names></name><name><surname>Buckley</surname><given-names>BM</given-names></name></person-group><article-title>Statins do more than just lower cholesterol</article-title><source>Lancet</source><year>1996</year><volume>348</volume><issue>9034</issue><fpage>1079</fpage><lpage>1082</lpage><comment>Erratum in: Lancet. 1997;349(9046):214</comment><pub-id pub-id-type="pmid">8874463</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treasure</surname><given-names>CB</given-names></name><name><surname>Klein</surname><given-names>JL</given-names></name><name><surname>Weintraub</surname><given-names>WS</given-names></name><name><surname>Talley</surname><given-names>JD</given-names></name><name><surname>Stillabower</surname><given-names>ME</given-names></name><name><surname>Kosinski</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Beneficial effects of cholesterol-lowering therapy on the
coronary endothelium in patients with coronary artery
disease</article-title><source>N Engl J Med</source><year>1995</year><volume>332</volume><issue>8</issue><fpage>481</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">7830728</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Chi</surname><given-names>J</given-names></name></person-group><article-title>Rosuvastatin inhibits MMP-2 expression and limits the progression
of atherosclerosis in LDLR-deficient mice</article-title><source>Arch Med Res</source><year>2009</year><volume>40</volume><issue>5</issue><fpage>345</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">19766896</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obi</surname><given-names>C</given-names></name><name><surname>Wysokinski</surname><given-names>W</given-names></name><name><surname>Karnicki</surname><given-names>K</given-names></name><name><surname>Owen</surname><given-names>WG</given-names></name><name><surname>McBane</surname><given-names>RD</given-names><suffix>2nd</suffix></name></person-group><article-title>Inhibition of platelet-rich arterial thrombus in vivo: acute
antithrombotic effect of intravenous HMG-CoA reductase
therapy</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2009</year><volume>29</volume><issue>9</issue><fpage>1271</fpage><lpage>1276</lpage><pub-id pub-id-type="pmid">19667107</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Morrow</surname><given-names>D</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><name><surname>Rose</surname><given-names>LM</given-names></name><name><surname>McCabe</surname><given-names>CH</given-names></name><etal/><collab>Pravastatin or Atorvastatin Evaluation and Infection
Therapy-Thrombolysis in Myocardial Infarction 22 Investigators</collab></person-group><article-title>C-reactive protein levels and outcomes after statin
therapy</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><issue>1</issue><fpage>20</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">15635109</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>MH</given-names></name><name><surname>McGarry</surname><given-names>T</given-names></name><name><surname>Bettis</surname><given-names>R</given-names></name><name><surname>Melani</surname><given-names>L</given-names></name><name><surname>Lipka</surname><given-names>LJ</given-names></name><name><surname>LeBeaut</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Ezetimibe coadministered with simvastatin in patients with
primary hypercholesterolemia</article-title><source>J Am Coll Cardiol</source><year>2002</year><volume>40</volume><issue>12</issue><fpage>2125</fpage><lpage>2134</lpage><pub-id pub-id-type="pmid">12505224</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sudhop</surname><given-names>T</given-names></name><name><surname>Lutjohann</surname><given-names>D</given-names></name><name><surname>Kodal</surname><given-names>A</given-names></name><name><surname>Igel</surname><given-names>M</given-names></name><name><surname>Tribble</surname><given-names>DL</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name><etal/></person-group><article-title>Inhibition of intestinal cholesterol absorption by ezetimibe in
humans</article-title><source>Circulation</source><year>2002</year><volume>106</volume><issue>15</issue><fpage>1943</fpage><lpage>1948</lpage><pub-id pub-id-type="pmid">12370217</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rifai</surname><given-names>N</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name><name><surname>Ridker</surname><given-names>PM</given-names></name></person-group><article-title>Clinical efficacy of an automated high-sensitivity C- reactive
protein assay</article-title><source>Clin Chem</source><year>1999</year><volume>45</volume><issue>12</issue><fpage>2136</fpage><lpage>2141</lpage><pub-id pub-id-type="pmid">10585345</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corretti</surname><given-names>MC</given-names></name><name><surname>Anderson</surname><given-names>TJ</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Celermajer</surname><given-names>D</given-names></name><name><surname>Charbonneau</surname><given-names>F</given-names></name><name><surname>Creager</surname><given-names>MA</given-names></name><etal/><collab>International Brachial Artery Reactivity Task Force</collab></person-group><article-title>Guidelines for the ultrasound assessment of endothelial-dependent
flow-mediated vasodilation of the brachial artery: a report of the
International Brachial Artery Reactivity Task Force</article-title><source>J Am Coll Cardiol</source><year>2002</year><volume>39</volume><issue>2</issue><fpage>257</fpage><lpage>265</lpage><comment>Erratum in: J Am Coll Cardiol. 2002;39(6):1082</comment><pub-id pub-id-type="pmid">11788217</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moens</surname><given-names>AL</given-names></name><name><surname>Goovaerts</surname><given-names>I</given-names></name><name><surname>Claeys</surname><given-names>MJ</given-names></name><name><surname>Vrints</surname><given-names>CJ</given-names></name></person-group><article-title>Flow mediated vasodilation: a diagnostic instrument or an
experimental tool?</article-title><source>Chest</source><year>2005</year><volume>127</volume><issue>6</issue><fpage>2254</fpage><lpage>2263</lpage><pub-id pub-id-type="pmid">15947345</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westerink</surname><given-names>J</given-names></name><name><surname>Deanfield</surname><given-names>JE</given-names></name><name><surname>Imholz</surname><given-names>BP</given-names></name><name><surname>Spiering</surname><given-names>W</given-names></name><name><surname>Basart</surname><given-names>DC</given-names></name><name><surname>Coll</surname><given-names>B</given-names></name><etal/></person-group><article-title>High-dose statin monotherapy versus low-dose statin/ezetimibe
combination on fasting and postprandial lipids and endothelial function in
obese patients with the metabolic syndrome: the PANACEA
study</article-title><source>Atherosclerosis</source><year>2013</year><volume>227</volume><issue>1</issue><fpage>118</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">23261174</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Settergren</surname><given-names>M</given-names></name><name><surname>Bohm</surname><given-names>F</given-names></name><name><surname>Ryden</surname><given-names>L</given-names></name><name><surname>Pernow</surname><given-names>J</given-names></name></person-group><article-title>Cholesterol lowering is more important than pleiotropic effects
of statins for endothelial function in patients with dysglycaemia and
coronary artery disease</article-title><source>Eur Heart J</source><year>2008</year><volume>29</volume><issue>14</issue><fpage>1753</fpage><lpage>1760</lpage><pub-id pub-id-type="pmid">18441323</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>PY</given-names></name><name><surname>Liu</surname><given-names>YW</given-names></name><name><surname>Lin</surname><given-names>LJ</given-names></name><name><surname>Chen</surname><given-names>JH</given-names></name><name><surname>Liao</surname><given-names>JK</given-names></name></person-group><article-title>Evidence for statin pleiotropy in humans: differential effects of
statins and ezetimibe on rho-associated coiled-coil containing protein
kinase activity, endothelial function, and inflammation</article-title><source>Circulation</source><year>2009</year><volume>119</volume><issue>1</issue><fpage>131</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">19075102</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gemignani</surname><given-names>V</given-names></name><name><surname>Faita</surname><given-names>F</given-names></name><name><surname>Ghiadoni</surname><given-names>L</given-names></name><name><surname>Poggianti</surname><given-names>E</given-names></name><name><surname>Demi</surname><given-names>M</given-names></name></person-group><article-title>A system for real-time measurement of the brachial artery
diameter in B-mode ultrasound images</article-title><source>IEEE Trans Med Imaging</source><year>2007</year><volume>26</volume><issue>3</issue><fpage>393</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">17354644</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meirelles Cde</surname><given-names>M</given-names></name><name><surname>Leite</surname><given-names>SP</given-names></name><name><surname>Montenegro</surname><given-names>CA</given-names></name><name><surname>Gomes</surname><given-names>PS</given-names></name></person-group><article-title>Reliability of brachial artery flow-mediated dilatation
measurement using ultrasound</article-title><source>Arq Bras Cardiol</source><year>2007</year><volume>89</volume><issue>3</issue><fpage>160</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">17906817</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esposito</surname><given-names>K</given-names></name><name><surname>Pontillo</surname><given-names>A</given-names></name><name><surname>Di Palo</surname><given-names>C</given-names></name><name><surname>Giugliano</surname><given-names>G</given-names></name><name><surname>Masella</surname><given-names>M</given-names></name><name><surname>Marfella</surname><given-names>R</given-names></name><etal/></person-group><article-title>Effect of weight loss and lifestyle changes on vascular
inflammatory markers in obese women: a randomized trial</article-title><source>JAMA</source><year>2003</year><volume>289</volume><issue>14</issue><fpage>1799</fpage><lpage>1804</lpage><pub-id pub-id-type="pmid">12684358</pub-id></element-citation></ref></ref-list></back></article>